Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) Research & Development (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Research & Development for 6 consecutive years, with $31.5 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 51.63% to $31.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $125.9 million through Dec 2025, up 84.09% year-over-year, with the annual reading at $125.9 million for FY2025, 84.09% up from the prior year.
  • Research & Development for Q4 2025 was $31.5 million at Janux Therapeutics, down from $34.6 million in the prior quarter.
  • The five-year high for Research & Development was $34.7 million in Q2 2025, with the low at $1.9 million in Q1 2021.
  • Average Research & Development over 5 years is $16.4 million, with a median of $14.5 million recorded in 2022.
  • The sharpest move saw Research & Development surged 1033.91% in 2021, then fell 20.69% in 2023.
  • Over 5 years, Research & Development stood at $11.2 million in 2021, then soared by 38.19% to $15.4 million in 2022, then dropped by 20.69% to $12.2 million in 2023, then soared by 69.97% to $20.8 million in 2024, then soared by 51.63% to $31.5 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $31.5 million, $34.6 million, and $34.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.